<?xml version='1.0' encoding='utf-8'?>
<document id="26248976"><sentence text="Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring."><entity charOffset="30-43" id="DDI-PubMed.26248976.s1.e0" text="isavuconazole" /><entity charOffset="48-58" id="DDI-PubMed.26248976.s1.e1" text="tacrolimus" /><entity charOffset="98-108" id="DDI-PubMed.26248976.s1.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.26248976.s1.e0" e2="DDI-PubMed.26248976.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26248976.s1.e0" e2="DDI-PubMed.26248976.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26248976.s1.e0" e2="DDI-PubMed.26248976.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26248976.s1.e1" e2="DDI-PubMed.26248976.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26248976.s1.e1" e2="DDI-PubMed.26248976.s1.e2" /></sentence><sentence text="Despite the known significant drug-drug interaction between isavuconazole and tacrolimus, there are no recommendations on dose adjustment when these drugs are given concomitantly"><entity charOffset="60-73" id="DDI-PubMed.26248976.s2.e0" text="isavuconazole" /><entity charOffset="78-88" id="DDI-PubMed.26248976.s2.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.26248976.s2.e0" e2="DDI-PubMed.26248976.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26248976.s2.e0" e2="DDI-PubMed.26248976.s2.e1" /></sentence><sentence text=" We report on a patient with a mediastinal Aspergillus fumigatus infection resistant to posaconazole and describe how she was successfully managed with tacrolimus therapeutic drug-level monitoring"><entity charOffset="88-100" id="DDI-PubMed.26248976.s3.e0" text="posaconazole" /><entity charOffset="152-162" id="DDI-PubMed.26248976.s3.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.26248976.s3.e0" e2="DDI-PubMed.26248976.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26248976.s3.e0" e2="DDI-PubMed.26248976.s3.e1" /></sentence><sentence text="" /><sentence text="Our patient presented with a mediastial Aspergillus fumigatus infection, 2 years after lung transplantation" /><sentence text=" A" /><sentence text=" fumigatus was resistant to posaconazole, and the patient had intolerance to voriconazole shown by elevated transaminases"><entity charOffset="28-40" id="DDI-PubMed.26248976.s7.e0" text="posaconazole" /><entity charOffset="77-89" id="DDI-PubMed.26248976.s7.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.26248976.s7.e0" e2="DDI-PubMed.26248976.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26248976.s7.e0" e2="DDI-PubMed.26248976.s7.e1" /></sentence><sentence text=" The patient was given isavuconazole with drug-level monitoring"><entity charOffset="23-36" id="DDI-PubMed.26248976.s8.e0" text="isavuconazole" /></sentence><sentence text=" She was managed successfully with no adverse events" /><sentence text=" Tacrolimus concentration continued to increase after more than 2 weeks of therapy and required a further reduction to 72% of the usual dose to maintain the target concentrations over a 8-week period" /><sentence text="" /><sentence text="When isavuconazole is given to patients on tacrolimus, the dose of the latter will need considerable reduction"><entity charOffset="5-18" id="DDI-PubMed.26248976.s12.e0" text="isavuconazole" /><entity charOffset="43-53" id="DDI-PubMed.26248976.s12.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.26248976.s12.e0" e2="DDI-PubMed.26248976.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26248976.s12.e0" e2="DDI-PubMed.26248976.s12.e1" /></sentence><sentence text=" We would suggest an initial 50% reduction and recommend close weekly monitoring of tacrolimus concentration"><entity charOffset="84-94" id="DDI-PubMed.26248976.s13.e0" text="tacrolimus" /></sentence><sentence text=" Further dose decreases of 25-50% may be required" /><sentence text="" /></document>